Table 6:

Haplotype association to analyze the relationship between acute pain phenotypes and EREG haplotypes:

Cohort	Acute Pain Phenotype	n	prevalence	Haplotype II		Haplotype III
				ESTIMATE	FDR	ESTIMATE	FDR
OPPERA	Acute pain intensity	213	52.58%Ϯ	β = −1.83	0.517	β = 8.68	0.0390*
	Acute facial pain			OR = 0.76	0.289	OR = 1.99	0.121
UK biobank	Acute pain all over the body	335,565	0.87 %	OR = 1.01	0.909	OR = 1.33	0.0003**
	Acute stomach or Abdominal pain	352,780	5.34 %	OR = 0.99	0.261	OR = 0.94	0.066
	Acute headache	388,126	13.96 %	OR = 0.99	0.246	OR = 1.00	0.771
	Acute neck or shoulder pain	369,264	9.57 %	OR = 1.02	0.083	OR = 1.01	0.611
	Acute back pain	373,432	10.58 %	OR = 0.99	0.672	OR = 0.98	0.447
	Acute hip pain	346,291	3.57 %	OR = 0.99	0.820	OR = 0.98	0.758
	Acute knee pain	356,768	6.40 %	OR = 1.00	0.810	OR = 1.03	0.408
	Acute facial pain	338,577	1.37 %	OR = 0.97	0.405	OR = 0.95	0.541
	No. of acute pain sites	471,773	29.22 %Δ	β = −0.001	0.752	β = 0.028	0.003*
	At least one acute pain site			OR = 1.01	0.909	OR = 1.34	0.0002**

CPI: characteristic pain intensity; n: valid number of participants/cases and controls; number of controls (no pain at all) is 333,936 for all the UK biobank phenotypes;

^Ϯprevalence of participants with acute pain intensity at follow-up > 0 among n with valid acute acute pain intensity scores at follow-up; β: slope of least – squares line; OR: Odds Ratio;

^Δprevalence of at least one acute pain site. FDR: False Discovery Rate;

^‘**’:FDR < 0.001

^‘*’:0.05